Exicure, Inc. is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The Company, through GPCR Therapeutics USA Inc. (GPCR USA), is focused on developing and commercializing an intellectual property and patents related to G-Protein Coupled Receptors. GPCR USA is conducting a Phase II clinical trial for a blood cancer treatment involving GPC-100 (Burixafor). The Company is also exploring strategic alternatives to maximize stockholder value.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26/06/26	$2.400	-4.76%	68,980
25/06/26	$2.520	-6.32%	44,360
24/06/26	$2.690	-1.47%	31,171
23/06/26	$2.730	-0.36%	26,463
22/06/26	$2.740	+18.61%	185,413

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Market Closed - Nasdaq Other stock markets 00:00:00 27/06/2026 +04			5-day change	1st Jan Change
2.400 ^USD	-4.76%		+3.90%	-55.72%

05-29	Exicure, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-23	Exicure announces co-development agreement with Adbiotech for burixafor (GPC-100)	RE

Market Cap	15.3M 13.41M 12.36M 11.57M 21.7M 1.44B 22.16M 149M 57.5M 713M 57.44M 56.19M 2.47B	P/E 2024	-2.88x	P/E 2025	-6.9x
Enterprise Value	11.73M 10.28M 9.48M 8.87M 16.64M 1.11B 16.98M 114M 44.08M 547M 44.04M 43.07M 1.9B	EV / Sales 2024	70.2x	EV / Sales 2025	-
Free-Float	64.62%	Yield 2024 *	-	Yield 2025	-

05-29	Exicure, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-23	Exicure announces co-development agreement with Adbiotech for burixafor (GPC-100)	RE
04-23	Exicure, Inc. And Adbiotech Co., Ltd. Enter Co-Development Agreement For Burixafor (GPC-100)	CI
04-11	Exicure, Inc. Announces Management Changes	CI
03-28	Exicure, Inc. Announces Resignation of Director Sangjin Yeo from Board and Audit Committee, Effective March 27, 2026	CI
03-26	Exicure, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-25	Exicure, Inc. Auditor Raises 'Going Concern' Doubt	CI
02-18	Exicure appoints Jung Soo Kim as CEO and president	RE
02-18	Exicure, Inc. Announces Executive Appointments, Effective February 11, 2026	CI
02-18	Exicure, Inc. Appoints Gyuyeob Lee as Interim Chief Financial Officer, Effective February 11, 2026	CI
02-18	Exicure, Inc. Appoints Jung Soo Kim as Chief Executive Officer, Effective February 11, 2026	CI
02-11	Exicure, Inc. Announces Resignation of Seung Ik Baik as Chief Financial Officer, Effective February 9, 2026	CI
02-11	Exicure, Inc. Announces Resignation of Andy Yoo as Chief Executive Officer, Effective February 9, 2026	CI

16/08/22	Chardan Adjusts Exicure's Price Target to $2 on 1-for-30 Reverse Stock Split, Maintains Neutral Rating	MT
29/03/22	Chardan Adjusts Exicure's Price Target to $0.25 From $0.40 'on Increased Dilution;' Neutral Rating Kept	MT
13/12/21	Chardan Downgrades Exicure to Neutral From Buy After Probe Shows Clinical Data Misrepresentation, Lowers PT to $0.40 From $2.25	MT
23/11/21	Chardan Adjusts Price Target on Exicure to $2.25 From $7 'on Uncertain Delays for Clinical Programs,' Keeps Buy Rating	MT
17/05/21	EXICURE : HC Wainwright Adjusts Price Target on Exicure to $6 From $8, Maintains Buy Rating	MT

Exicure, Inc. Stock

Stocks

XCUR

US30205M3097

Biotechnology & Medical Research

Valuation: Exicure, Inc.

Chart: Exicure, Inc.

Latest news : Exicure, Inc.

Analysts' recommendations: Exicure, Inc.

Press Releases: Exicure, Inc.

News in other languages: Exicure, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Exicure, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

06-11	Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement	AQ
06-02	Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q	AQ
04-23	Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)	AQ
04-03	Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions	AQ
03-26	Exicure, Inc. Reports Full Year 2025 Financial Results	AQ

02/08/21	Les valeurs à suivre aujourd'hui à Paris Lundi 2 août 2021
02/08/21	Ipsen : signe un partenariat avec Exicure dans les acides nucléiques sphériques
02/08/21	EN DIRECT DES MARCHES : Axa, Bolloré, Neoen, Ipsen, HSBC, Heineken, Square, Moderna...
02/08/21	Ipsen : accord de collaboration avec Exicure
02/08/21	Dernière ligne droite avant la coupure aoûtienne

1 day	-4.76%
1 week	+3.90%
Current month	-24.76%
1 month	-10.24%
3 months	-47.94%
6 months	-59.93%
Current year	-55.72%

1 week	2.4	3.2
1 month	1.71	3.45
Current year	1.71	6.64
1 year	1.71	9.5
3 years	1.44	36
5 years	1.44	297
10 years	1.44	975

Manager	Title	Age	Since
Jungsoo Kim CEO	Chief Executive Officer	-	11/02/2026
Josephine Cardarelli PSD	President	-	06/10/2025
Gyuyeob Lee DFI	Director of Finance/CFO	40	11/02/2026

Director	Title	Age	Since
Dongho Lee BRD	Director/Board Member	64	21/08/2023
Jungsoo Kim BRD	Director/Board Member	-	11/02/2026
Jung Kyu Ham BRD	Director/Board Member	-	09/02/2026

Date	Insider	Type	Main position	Quantity	% Market Cap.
02-16	Josh Miller	Tax	Chief Accounting Officer	8	0.0001%
01-21	EXICURE HITRON, INC.	Sell	Company	258,367	4.0895%
01-16	EXICURE HITRON, INC.	Sell	Company	734,747	11.6298%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EXICURE, INC.	-4.76%	+3.90%	-56.72%	-60.93%	15.3M
ARGENX SE	+0.33%	+1.37%	+64.03%	+119.11%	55.63B
WUXI APPTEC CO., LTD.	+0.82%	+15.05%	+79.93%	+84.34%	52.25B
BIONTECH SE	+1.36%	+0.36%	-14.06%	-14.69%	23.07B
INSMED INCORPORATED	-1.04%	+7.91%	+1.61%	+419.24%	22.41B
WUXI BIOLOGICS (CAYMAN) INC.	-0.18%	+7.20%	+32.16%	-14.07%	17.32B
GENMAB A/S	-1.10%	+4.00%	+28.70%	-34.51%	15.94B
PHARMAESSENTIA CORPORATION	-3.35%	+8.96%	+132.20%	+290.18%	13.47B
EXELIXIS, INC.	+2.89%	+5.51%	+27.11%	+181.45%	13.77B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+1.31%	+0.53%	+28.62%	-	12.43B
Average	-0.37%	+4.69%	+32.36%	+107.79%	22.63B
Weighted average by Cap.	+0.26%	+5.13%	+48.49%	+120.16%

	2024	2025
Net sales	500K 438K 404K 378K 709K 47.17M 724K 4.86M 1.88M 23.31M 1.88M 1.84M 80.83M	-
Net income	-9.7M -8.51M -7.84M -7.34M -13.76M -915M -14.05M -94.24M -36.46M -452M -36.43M -35.63M -1.57B	-4.95M -4.34M -4M -3.74M -7.02M -467M -7.16M -48.05M -18.59M -231M -18.57M -18.17M -800M
Net Debt	-6.46M -5.67M -5.22M -4.89M -9.17M -610M -9.36M -62.79M -24.3M -301M -24.27M -23.74M -1.04B	-3.57M -3.13M -2.89M -2.7M -5.07M -337M -5.17M -34.68M -13.42M -166M -13.41M -13.11M -577M